Characterization of TrypZean: a Plant-Based Alternative to Bovine-Derived Trypsin (Peer-Reviewed) - An in-depth characterization of maize-derived trypsin revealed an unusual nonconsensus N-linked glyc

ADVERTISEMENT

Characterization of TrypZean: a Plant-Based Alternative to Bovine-Derived Trypsin (Peer-Reviewed)
An in-depth characterization of maize-derived trypsin revealed an unusual nonconsensus N-linked glycosylation.


BioPharm International
Volume 24, Issue 10, pp. 44-48

ABSTRACT

Recombinant bovine trypsin has been produced in transgenic maize as a pathogen-free alternative to the animal-derived reagent. Biological reagents intended for pharmaceutical purposes require comprehensive analysis including detailed information about sequence and posttranslational modifications. In this study, several techniques, including mass spectroscopy (MS) analysis of the intact protein, peptide mapping, and MS analysis of released glycans were applied and an in-depth characterization of maize derived trypsin was achieved, revealing an unusual nonconsensus N-linked glycosylation.

The protease enzyme trypsin is produced in the pancreas and has many uses in the pharmaceutical sector. As well as being used to digest proteins for laboratory analysis, where it specifically cleaves at arginine and lysine residues, it also has applications in pharmaceutical production, such as producing insulin from pro-insulin and making vaccines. For any pharmaceutical process, it is essential that the enzyme is free from pathogens, which may be present in animal-derived products.

The increasing desire of industry to avoid reagents from animal sources has inspired many attempts to express bovine trypsin in alternative platforms. For that reason, the expression of trypsin in maize for large-scale industrial and pharmaceutical applications was developed and optimized by Woodard et al. (1). The task was accomplished by expressing the enzyme in an inactive zymogen form that accumulates in the endosperm of the maize seeds. The zymogen gene was inserted into maize plants and cultivated in open fields. The purified enzyme is currently commercialized by Sigma-Aldrich under the trade name TrypZean. While more expensive than animal-derived trypsin, its cost is more than offset by the elimination of regulatory costs associated with viral-clearance studies that are needed when using the animal product.


Table I: Physicochemical properties of native bovine trypsin and TrypZean.
The biophysical and chemical properties of TrypZean and native bovine trypsin are compared in Table I. TrypZean has the same amino-acid sequence as the bovine-sourced product. Functionally, its activity appears to be identical to that of the native bovine protein. However, pancreatic trypsin is not glycosylated, whereas characterization of the maize-derived trypsin has shown that corn glycosylates the enzyme. It was important to pinpoint precisely where the protein was glycosylated, so that the exact structure could be known for pharmaceutical applications, and to fully understand the biological processes. To provide this full characterization, a novel way of preparing the samples was developed.

GLYCOSYLATED PROTEIN ANALYSIS STRATEGIES

Glycosylation is a common post-translational modification, with around half of all human proteins bearing some form of sugar functionality. There are two major forms of glycosylation, O- and N-linked. For O-glycosylation, the sugar can be attached to the hydroxyl group of a serine or threonine residue anywhere in the protein. For N-glycosylation, a well-defined rule states where in a protein sequence N-glycosylation can occur: it is always attached to the amide group of an asparagine residue that is followed first by any amino acid other than proline, and then either serine or threonine. This so-called consensus sequence does not occur in trypsin, which implied that TrypZean was O-glycosylated.

The following are the three standard methods for the analysis of glycosylated proteins using mass spectrometry (MS):

1. Liberation of the glycans from the protein by chemical or enzymatic means, followed by derivatization of the glycan before MS analysis

2. MS analysis of the intact protein with no pretreatment (i.e., top-down strategy)

3. Peptide mapping, with proteolytic digestion of the glycosylated protein followed by MS analysis of the resulting digest (i.e., bottom-up strategy).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here